For decades, people with advanced age-related macular degeneration (AMD) — the leading cause of irreversible blindness in older adults — have been told that once vision is lost, it’s gone forever. But a new study has changed that narrative.
In a clinical trial published in the New England Journal of Medicine, researchers reported that 27 out of 32 participants regained the ability to read after receiving a wireless retinal implant called PRIMA.
“It’s the first time that any attempt at vision restoration has achieved such results in a large number of patients,” said José-Alain Sahel, chair of the Department of Ophthalmology at the University of Pittsburgh’s School of Medicine.
More than 80% of patients in the study saw clinically meaningful improvement, and most could read letters, words, and in some cases, even pages in a book. “More than 80% of the patients were able to read letters and words, and some of them are reading pages in a book,” Sahel added. The results, researchers say, signal the arrival of a new generation of bionic vision technology — one that restores function, not just slows degeneration.
How the PRIMA chip recreates sightThe PRIMA device replaces dead light-sensing photoreceptors in the retina — the cells responsible for converting light into electrical signals. The implant, a 2×2 mm wireless chip as thin as plastic wrap, is inserted directly into the retina to act as a prosthetic substitute for the lost photoreceptors.
A camera mounted on specialised glasses captures images from the environment, which are then converted into near-infrared light and projected onto the implant. Inside the eye, the implant translates those light signals into electrical pulses that stimulate the surviving retinal neurons — reactivating the visual pathway to the brain. The process allows patients to perceive shapes, patterns, and letters, though the vision remains black-and-white and limited in clarity.
“This is at the forefront of science,” said
Dr Demetrios Vavvas, director of the retina service at Massachusetts Eye and Ear, Boston. Though not involved in the study, he called the breakthrough “the dawn of a new technology” and predicted it would significantly advance in the coming years.
More than 80% of the patients were able to read letters and words, and some of them are reading pages in a book. It’s the first time any attempt at vision restoration has achieved such results
José-Alain Sahel, Chair, department of ophthalmology, University of Pittsburgh
The restored vision isn’t normal — it’s blurry, monochrome, and the field of view is small. But even limited vision has proven transformative. On average, patients gained five lines on a standard eye chart, and one participant improved by as many as 59 letters — equivalent to 12 lines. Some can now recognise faces, navigate surroundings, or read short passages using a zoom feature on the glasses.
The trial involved older adults with an average age of 79, most of whom had long-lost central vision to geographic atrophy, a severe form of AMD. “The idea that such patients could get some vision back is amazing,” said Dr Royce W. Chen, macular degeneration expert at Columbia University Irving Medical Center. Dr Ronald Adelman, chair of ophthalmology at the Mayo Clinic in Florida, agreed: “This brings hope,” he said. Still, experts caution that it’s not a cure. The implant helps only those who have lost retinal photoreceptors, and not other forms of blindness.
Challenges, side effects, next stepsThe surgery is not without risks. Out of the 38 participants who received the implant, 19 experienced side effects, including increased eye pressure, retinal tears, and bleeding. According to the researchers, “These side effects were mostly manageable and resolved within two months.”
“Among the 32 participants who completed 12 months of follow-up, the PRIMA system led to a clinically meaningful improvement in visual acuity from baseline in 26 (81%),” the study noted. Using multiple imputation for missing data, researchers estimated that 80% of all participants would show such improvement after one year. Despite early challenges, the researchers are optimistic. Daniel Palanker, the Stanford University physicist who invented the PRIMA chip, said: “We thought that [the old design with wires in the eye] was the wrong design.” The wireless model, he said, offers a safer, scalable path forward — and his team is already testing an improved version with higher resolution. “It has worked in preliminary tests,” Palanker said — “in rats”.
Currently, treatments only slow AMD’s progression — meaning patients “get worse slower”, as Dr Chen put it. The PRIMA system, by contrast, offers functional restoration. The implications are enormous. Over 5 million people globally suffer from geographic atrophy — most with no hope of recovery. For them, even a blurry black-and-white window into the world represents liberation from total darkness.
Source: New England Journal of Medicine and agencies
Follow Us On Social Media